Board Appointment

Tristel PLC 03 April 2008 Tristel plc ('Tristel' or 'the Company') Board Appointment Tristel plc, the AIM listed provider of infection and contamination control products, announces the appointment of Mr Bruce Green as a non-executive director to the Board with immediate effect. Mr Green, aged 63, has acted as a consultant to Tristel since the incorporation of the Company in 1993. He is the original inventor/pioneer of Tristel's proprietary chlorine dioxide technology and signed over the patents to Tristel at its admission to AIM in June 2005. Mr Green is currently interested in 864,016 Ordinary 1p Shares, representing 3.2 per cent. of the Company' issued share capital. Mr Green is a Chartered Scientist, a Chartered Chemist and a member of the Royal Society of Chemistry. For the last 25 years Mr Green has acted as an independent consultant and formulator in the infection control, cosmetics and food hygiene industries. Pursuant to Rule 17, Schedule Two (g) of the AIM Rules for Companies the following information is disclosed: Current Appointments Bruce Green Limited Food Safe Sales Limited Food Safe Limited (dormant) Floraceuticals Limited (dormant) Toby Brown Limited (dormant) Browns Cosmetics Limited (dormant) Browns Haircare Limited (dormant) Previous Appointments Hairology Limited Claremont & May of Canterbury Limited Boxercise Limited Rugby Polo Club Limited Manufacturing Packaging Services Limited Health and Hygiene International Limited Formulas To Go Limited First Rung Housing Aqua Safe Technology Limited The Real Soil Associates Limited Mr Green was a Director of Janda Chemicals Limited at the time of its liquidation, following the non payment of monies due from a creditor to Janda Chemicals Limited. There is no further information to disclose. Tristel plc Paul Swinney, Chief Executive Tel: 01638 721 500 Daniel Stewart & Company Plc Graham Webster Tel: 020 7776 6576 Parkgreen Communications Ltd Tel: 020 7851 7480 Lucy Lake Mob: 07894 263 046 lucy.lake@parkgreenmedia.com Notes to Editors Tristel's core business is the marketing of its proprietary chlorine dioxide chemistry that is highly effective in destroying all types of bacteria (including C difficile, MRSA, bacterial spores, and tuberculosis), fungi and viruses and is one of a small group of sporicidal agents that is safe and easy to use. Tristel plc operates with two divisions, Tristel Solutions and Tristel Technologies. Tristel Solutions focuses on infection control products for NHS and private sector hospitals, primary care trusts, community hospitals, private practices, dental practices and veterinary establishments. The Company's products are used on instruments, surfaces, and the skin in over 375 UK hospitals, representing some 60 per cent of all UK NHS Acute & Private Hospitals. Tristel Technologies provides products for Legionella infection control in building water systems and for contamination control in the food growing and food processing industries. Tristel Technologies has approximately 200 customers in the government, municipal, industrial, healthcare and food sectors and more 40 UK hospitals where its products are used for Legionella control. This information is provided by RNS The company news service from the London Stock Exchange

Companies

Tristel (TSTL)
UK 100

Latest directors dealings